Boston Scientific Corporation
BSXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company carries a $65.44B market cap, placing it firmly in the large-cap category. The company operates in two segments, MedSurg and Cardiovascular.
Market Cap
$65.44B
Beta
0.58
P/E (TTM)
18.66
P/E (Fwd)
11.88
EPS (TTM)
$2.36
EPS (Fwd)
$3.71
ROE
14.7%
ROA
6.1%
Cash
$1.45B
Total Debt
$11.03B
Free CF
$2.81B
52W Change
-57.5%
Annual Financials
Cash vs Debt
On the balance sheet, BSX has $1.45B in cash with $11.03B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $2.81B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 14.7%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $12.68B (2022) to $20.07B (2025), reflecting a 58% increase over the period.
With a beta below 0.7, Boston Scientific Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BSX.